Lupin

Market Cap: Large Cap
Industry: Pharmaceuticals & Drugs
ISIN: INE326A01037
NSEID: LUPIN
BSEID: 500257

INR

1,980.00

58.7 (3.06%)

BSENSE

Apr 11, 12:53 PM

BSE+NSE Vol: 6.22 lacs

Click here to access the older version

Company CV

About Lupin Ltd.

Lupin Ltd.

Large Cap

Pharmaceuticals & Drugs

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Company Coordinates

Company Details

Kalpataru Inspire 3rd Floor, Off Western Exp HW Santacruz-E Mumbai Maharashtra : 400055

Tel: 91-22-6640 2323

http://www.lupin.com

info@lupin.com

Registrar Details

Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai

Capital Structure

Present Equity Capital

INR 91.23 Cr

Number of Shares

45.61 Cr

Face Value

INR 2.0

Date

Number
of Shares(Cr)

Equity
Capital (Rs Cr)

Shares Added

Face Value (Rs)

Reason

28-Aug-2024

45.61

91.23

121150

Issued under ESOP Scheme

26-Jul-2024

45.6

91.20

57384

Issued under ESOP Scheme

09-Jul-2024

45.6

91.19

42932

Issued under ESOP Scheme

21-Jun-2024

45.59

91.18

43475

Issued under ESOP Scheme

21-May-2024

45.59

91.17

122374

Issued under ESOP Scheme

18-Apr-2024

45.58

91.15

59809

Issued under ESOP Scheme

03-Apr-2024

45.57

91.14

11387

Issued under ESOP Scheme

21-Mar-2024

45.57

91.14

52041

Issued under ESOP Scheme

22-Feb-2024

45.56

91.13

137917

Issued under ESOP Scheme

24-Jan-2024

45.55

91.10

162400

Issued under ESOP Scheme

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 35 Schemes (16.92%)

FIIs

Held by 861 FIIs (22.04%)

Promoter with highest holding

Lupin Investments Pvt Ltd (45.41%)

Highest Public shareholder

Hdfc Trustee Company Ltd-hdfc Balanced Advantage Fund (3.36%)

Individual Investors Holdings

5.17%

Board of Directors

Period

Management

Designation

Remuneration

M D Gupta

Chairman (Non-Executive)

14.5 lacs

Nilesh Deshbandhu Gupta.

Managing Director

4.96 cr

Vinita Gupta

Director & Chief Executive Off

10.92 cr

R V Satam

Company Sec. & Compli. Officer

Jean-Luc Belingard

Independent Director

13.9 lacs

Ramesh Swaminathan

Executive Director & CFO

7.74 cr

Mark D McDade

Independent Director

14.5 lacs

K B S Anand

Independent Director

15.7 lacs

Punita Kumar Sinha

Independent Director

16.5 lacs

Raw Materials

Raw Materials Dashboard

Raw Materials

Amount(Rs Cr)

% of RM Cost

No Data Available for Raw Material Segmentation

No Data Available

Finished Goods

Finished Goods Dashboard

Finished Goods

Amount(Rs Cr)

% of Sales Turnover

Pharmaceuticals

10,657.30

93.84%

Income from Research Services

374.24

3.30%

Other Operating Revenue - Export Benefits and Other Incentives

250.66

2.21%

Pharmaceuticals

Income from Research Services

Other Operating Revenue - Export Benefits and Other Incentives

Stock DNA

Revenue and Profits:

Net Sales:

5,768 Cr

(Quarterly Results - Dec 2024)

Net Profit:

855 Cr

Industry

Pharmaceuticals & Drugs

Market cap

INR 90,400 Cr (Large Cap)

P/E

31.00

Industry P/E

Dividend Yield

0.42%

Debt Equity

0.03

Return on Equity

16.79%

Price to Book

5.61